NCCN Recommends Zanubrutinib as First-Line, Second-Line Therapy in CLL/SLL
Join us online for our next Chronic Lymphocytic Leukemia webinar where experts discuss CLL information highly relevant to patients, caregivers and advocates right now. Participants will have the opportunity to submit questions to be answered live by our expert panel. Topics for discussion include:
- Treatment Options: Duration
- Treatment Options: Oral agents and drug adherence
- Patient-Physician Conversations: How to decide treatment
- Psychosocial: stress, anxiety between treatments/tests
Register now for access to CURE®’s community of leukemia and lymphoma experts.
Please see additional information and registration here.
Related posts
